Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity

Journal of Virology

Volumn 85, Issue 5, 2011, Pages 2364-2372

  Arita, Minetaro ^a   Kojima, Hirotatsu ^b   Nagano, Tetsuo ^b   Okabe, Takayoshi ^b   Wakita, Takaji ^a   Shimizu, Hiroyuki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; AN 12 H5; PHOSPHATIDYLINOSITOL 4 KINASE III BETA; PHOSPHATIDYLINOSITOL 4 PHOSPHATE KINASE; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOTRANSFERASE INHIBITOR; SMALL INTERFERING RNA; T 00127 HEV1; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SCREENING; VIRUS REPLICATION;

1-PHOSPHATIDYLINOSITOL 4-KINASE; ANTIVIRAL AGENTS; BENZIMIDAZOLES; ENTEROVIRUS; HEK293 CELLS; HUMANS; INDOLES; PHENOLS; POLIOMYELITIS; POLIOVIRUS; SPECIES SPECIFICITY; VIRAL PROTEINS; VIRUS REPLICATION;

ENTEROVIRUS; HEPATITIS C VIRUS; POLIOVIRUS;

EID: 79551707738     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02249-10     Document Type: Article

References (50)

1. Arita, M., Y. Ami, T. Wakita, and H. Shimizu. 2008. Cooperative effect of the attenuation determinants derived from poliovirus Sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J. Virol. 82:1787-1797. (Pubitemid 351206928)
2. Arita, M., N. Nagata, T. Sata, T. Miyamura, and H. Shimizu. 2006. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J. Gen. Virol. 87:3317-3327.
3. Arita, M., Y. Takebe, T. Wakita, and H. Shimizu. 2010. A bifunctional anti-enterovirus compound that inhibits replication and early stage of enterovirus 71 infection. J. Gen. Virol. 91:2734-2744.
4. Arita, M., T. Wakita, and H. Shimizu. 2009. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J. Gen. Virol. 90:1869-1879.
5. Arita, M., T. Wakita, and H. Shimizu. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J. Gen. Virol. 89:2518-2530.
6. Bain, J., et al. 2007. The selectivity of protein kinase inhibitors; a further update. Biochem. J. 408:297-315.
7. Baltera, R. F., Jr., and D. R. Tershak. 1989. Guanidine-resistant mutants of poliovirus have distinct mutations in peptide 2C. J. Virol. 63:4441-4444.
8. Barton, D. J., and J. B. Flanegan. 1997. Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C. J. Virol. 71:8482-8489.
9. Belov, G. A., Q. Feng, K. Nikovics, C. L. Jackson, and E. Ehrenfeld. 2008. A critical role of a cellular membrane traffic protein in poliovirus RNA replication. PLoS Pathog. 4:e1000216.
10. Berger, K. L., et al. 2009. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. U. S. A. 106:7577-7582.
11. Bienz, K., D. Egger, M. Troxler, and L. Pasamontes. 1990. Structural organization of poliovirus RNA replication is mediated by viral proteins of the P2 genomic region. J. Virol. 64:1156-1163. (Pubitemid 20087753)
12. Bodian, D. 1949. Histopathologic basis of clinical findings in poliomyelitis. Am. J. Med. 6:563-578.
13. Borawski, J., et al. 2009. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J. Virol. 83:10058-10074.
14. Bordeleau, M. E., et al. 2006. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol. 2:213-220.
15. Brown-Augsburger, P., et al. 1999. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex. Arch. Virol. 144:1569-1585.
16. Caliguiri, L. A., and I. Tamm. 1968. Action of guanidine on the replication of poliovirus RNA. Virology 35:408-417.
17. Collett, M. S., J. Neyts, and J. F. Modlin. 2008. A case for developing antiviral drugs against polio. Antiviral Res. 79:179-187.
18. Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication, NRC. 2006. Exploring the role of antiviral drugs in the eradication of polio: workshop report. The National Academies Press, Washington, DC.
19. Couderc, T., et al. 1989. Molecular pathogenesis of neural lesions induced by poliovirus type 1. J. Gen. Virol. 70:2907-2918.
20. Crotty, S., M. C. Saleh, L. Gitlin, O. Beske, and R. Andino. 2004. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. J. Virol. 78:3378-3386. (Pubitemid 38568279)
21. Cuconati, A., A. Molla, and E. Wimmer. 1998. Brefeldin A inhibits cell-free, de novo synthesis of poliovirus. J. Virol. 72:6456-6464. (Pubitemid 28323959)
22. De Palma, A. M., et al. 2008. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J. Virol. 82:4720-4730. (Pubitemid 351657034)
23. De Palma, A. M., et al. 2008. Potential use of antiviral agents in polio eradication. Emerg. Infect. Dis. 14:545-551.
24. De Palma, A. M., et al. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 53:1850-1857.
25. Dierssen, U., F. Rehren, C. Henke-Gendo, G. Harste, and A. Heim. 2008. Rapid routine detection of enterovirus RNA in cerebrospinal fluid by a one-step real-time RT-PCR assay. J. Clin. Virol. 42:58-64.
26. Eggers, H. J., and I. Tamm. 1961. Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole. J. Exp. Med. 113:657-682.
27. Fox, M. P., M. J. Otto, and M. A. McKinlay. 1986. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob. Agents Chemother. 30:110-116.
28. Geller, R., M. Vignuzzi, R. Andino, and J. Frydman. 2007. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 21:195-205. (Pubitemid 46155813)
29. Heinz, B. A., and L. M. Vance. 1995. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 69:4189-4197.
30. Hsu, N. Y., et al. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811.
31. Irurzun, A., L. Perez, and L. Carrasco. 1992. Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A. Virology 191:166-175.
32. Knight, Z. A., et al. 2006. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733-747.
33. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
34. Macejak, D. G., and P. Sarnow. 1992. Association of heat shock protein 70 with enterovirus capsid precursor P1 in infected human cells. J. Virol. 66:1520-1527.
35. Mahboobi, S., et al. 2006. Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 49:3101-3115.
36. Matthews, D. A., et al. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U. S. A. 96:11000-11007.
37. Maynell, L. A., K. Kirkegaard, and M. W. Klymkowsky. 1992. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 66:1985-1994.
38. Molla, A., C. U. Hellen, and E. Wimmer. 1993. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J. Virol. 67:4688-4695. (Pubitemid 23215948)
39. Patick, A. K., et al. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 43:2444-2450.
40. Pevear, D. C., et al. 1989. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J. Virol. 63:2002-2007. (Pubitemid 19107797)
41. Pfister, T., and E. Wimmer. 1999. Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. J. Biol. Chem. 274:6992-7001.
42. Rodriguez, P. L., and L. Carrasco. 1992. Gliotoxin: inhibitor of poliovirus RNA synthesis that blocks the viral RNA polymerase 3Dpol. J. Virol. 66:1971-1976.
43. Sabin, A. B. 1965. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA 194:872-876.
44. Salk, J. E., et al. 1954. Studies in human subjects on active immunization against poliomyelitis. II. A practical means for inducing and maintaining antibody formation. Am. J. Public Health Nations Health 44:994-1009.
45. Shimizu, H., et al. 2000. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J. Virol. 74:4146-4154. (Pubitemid 30214420)
46. Vance, L. M., N. Moscufo, M. Chow, and B. A. Heinz. 1997. Poliovirus 2C region functions during encapsidation of viral RNA. J. Virol. 71:8759-8765.
47. Verlinden, Y., A. Cuconati, E. Wimmer, and B. Rombaut. 2000. The antiviral compound 5-(3,4-dichlorophenyl) methylhydantoin inhibits the post-synthetic cleavages and the assembly of poliovirus in a cell-free system. Antiviral Res. 48:61-69.
48. Wakita, T., et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
49. Wei, A. Z., I. Mayr, and W. Bode. 1988. The refined 2.3 A crystal structure of human leukocyte elastase in a complex with a valine chloromethyl ketone inhibitor. FEBS Lett. 234:367-373.
50. Wikel, J. H., et al. 1980. Synthesis of syn and anti isomers of 6-[[(hydroxyimino) phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidaz ol-2-amine. Inhibitors of rhinovirus multiplication. J. Med. Chem. 23:368-372.